Related Experiment Videos
Emerging drugs in Tourette syndrome
Yavuz S Silay1, Joseph Jankovic
1Parkinson's disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin Suite 1801, Houston, TX 77030, USA.
Expert Opinion on Emerging Drugs
|June 7, 2005
Summary
Patient education and individualized treatment are key for Tourette syndrome (TS). Medications like antidopaminergic agents target tics, while other drugs manage common comorbidities such as ADHD and OCD.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Tourette syndrome (TS) management requires careful consideration of symptom severity and impact on daily life.
- Patient education and behavioral interventions are foundational, with medication considered for significant functional impairment.
Purpose of the Study:
- To review existing and emerging medical treatments for tics in Tourette syndrome.
- To discuss the management of comorbid behavioral disorders frequently associated with TS.
Main Methods:
- Review of current literature on pharmacological and non-pharmacological treatments for TS.
- Analysis of drug classes including antidopaminergic agents, selective serotonin reuptake inhibitors, and psychostimulants.
Main Results:
- Antidopaminergic agents are effective for tics, though comparative trials on efficacy and side effects are limited.
- SSRIs are recommended for obsessive-compulsive behaviors, and psychostimulants for ADHD, despite potential transient tic increase.
Conclusions:
- Treatment for TS must be individualized, targeting the most bothersome symptoms first.
- A comprehensive approach addressing both tics and comorbid conditions is essential for optimal patient outcomes.